Small Molecules

01 Apr 2019 Shionogi Announces Submission of Cefiderocol Marketing Authorisation Application
01 Apr 2019 Selumetinib Granted US Breakthrough Therapy Designation in Neurofibromatosis Type 1
01 Apr 2019 PellePharm Initiates Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome
01 Apr 2019 Peloton Therapeutics Announces Clinical Data Update for PT2977 at European International Kidney Cancer Symposium
01 Apr 2019 Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe
01 Apr 2019 BlackThorn Therapeutics Announces Positive Phase 1 Results for Its Selective KOR Antagonist, BTRX-335140
01 Apr 2019 Recida Therapeutics Announces the Initiation of a Phase I Clinical Trial of RC-01, a Novel LpxC Inhibitor
30 Mar 2019 ESSA Pharma Announces Nomination of EPI-7386 as Lead Clinical Candidate in Metastatic Castration-Resistant Prostate Cancer
30 Mar 2019 Sangamo Therapeutics Presents New Preclinical Data Demonstrating Significant Reduction In Tau Expression With Gene Regulation Technology
30 Mar 2019 Data Safety Monitoring Board Recommends Continuation Of Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease
30 Mar 2019 FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis
30 Mar 2019 Chi-Med Initiates a Phase IIb/III Trial of Surufatinib in Patients with Unresectable or Metastatic Biliary Tract Cancer in China
30 Mar 2019 Velicept Therapeutics Announces Positive Top-Line Phase 2b Results for Solabegron in the Treatment of Overactive Bladder (OAB)
30 Mar 2019 Gilead and Galapagos Announce Filgotinib Meets Primary and Key Secondary Endpoints in the Phase 3 FINCH 1 Rheumatoid Arthritis Study
30 Mar 2019 Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients
30 Mar 2019 Antibe Therapeutics Announces Commencement of Phase 2B Dose-Ranging, Efficacy Study for Lead Drug, ATB-346
30 Mar 2019 Celgene Receives CHMP Positive Opinions for Both REVLIMID® (lenalidomide) and IMNOVID® (pomalidomide)-Based Triplet Combination Regimens for Patients with Multiple Myeloma
28 Mar 2019 Clarus Therapeutics Receives U.S. FDA Approval of JATENZO® (Testosterone Undecanoate Capsules for Oral Use) (CIII) for Testosterone Replacement Therapy in Certain Adult Men
27 Mar 2019 Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Major Depressive Disorder
27 Mar 2019 Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness
27 Mar 2019 Urovant Sciences Initiates Phase 3 Clinical Program with Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia
27 Mar 2019 Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
26 Mar 2019 Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson
26 Mar 2019 Astellas Presents Fezolinetant Phase 2b Clinical Trial Results at Endocrine Society's Annual Meeting (ENDO)
26 Mar 2019 Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up